A Phase 4 interventional study of Intravitreal Aflibercept Injection (IAI) in Age - Related Macular Degeneration (AMD), sponsored by Regeneron Pharmaceuticals. Completed at 49 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-12-22.
Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 21st largest by enrollment, is one of 5 that started in 2012, is one of 27 in phase 4, and was the 11th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 5 started in 2012.
This study's enrollment of 154 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
17 studies in Macular Degeneration by Regeneron Pharmaceuticals: 2 open now, 3 under way, 2 of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 17 studies in Macular Degeneration by Regeneron Pharmaceuticals, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2012, is the only one in phase 4, and was the 7th registered.
Regeneron Pharmaceuticals’s Macular Degeneration studies by the year they started, since 2005.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Regeneron Pharmaceuticals’s 17 in Macular Degeneration:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria include but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Intravitreal Aflibercept Injection (IAI)
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF)
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.
Time frame: Baseline to Week 100
Percentage of Participants Whose Optical Coherence Tomography (OCT) Status Was "Dry" at Week 52 and at Week 100 (LOCF)
Retinal fluid status was evaluated using spectral domain OCT on the study eye at every study visit. Last observation carried forward (LOCF) method was used to impute missing data.
Time frame: Baseline to Week 100
Percentage of Participants Who Gained ≥15 ETDRS Letters Compared With Baseline at Week 52 and Week 100 (LOCF)
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.
Time frame: At week 52 and At week 100
Change From Baseline in Best Corrected Visual Acuity Score Through Week 52 (LOCF)
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.
Time frame: Baseline to Week 52
Percentage of Participants Who Gained ≥0, ≥5, ≥10, or ≥30 Letters From Baseline in BCVA Through Week 100 (LOCF)
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.
Time frame: Baseline to Week 100
Percentage of Patients Who Lost >0, ≥5, ≥10, or ≥15 Letters From Baseline in BCVA Through Week 100 (LOCF)
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.
Time frame: Baseline to Week 100
Percent Change From Baseline in Corneal Endothelial Cell Density (ECD) at Week 24 and Week 52 in the Study Eye and the Fellow Eye - Endothelial Cell Density Evaluable Set (EES)
EES included all eligible patients who were treated in the study eye, untreated in the fellow eye, had baseline specular microscopy image in both eyes, and completed week 52 evaluation in both eyes and treatment with systemic anti-VEGF therapeutics
Time frame: At week 24 and At week 52
The study was conducted at 43 sites in the US from 14Nov2012 to 03Sep2015. The target study population consisted of men and women 50 years of age and older with neovascular AMD who met all study eligibility criteria. A total of 288 patients were screened, of whom 154 patients were enrolled and treated. A total of 126 patients completed week 100.
| Milestone | Open Label IAI |
|---|---|
| Started | 154 |
| Completed | 126 |
| Not completed | 28 |
| Withdrew: Adverse event | 8 |
| Withdrew: Death | 3 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Protocol deviation | 1 |
| Withdrew: Physician decision | 3 |
| Withdrew: Relocation (did not wish to transfer) | 1 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.
| letters correctly read | Open Label IAI |
|---|---|
| Week 100 | 58.7 ± 20.5 |
| Change from Baseline at Week 100 | 4.5 ± 17.2 |
Retinal fluid status was evaluated using spectral domain OCT on the study eye at every study visit. Last observation carried forward (LOCF) method was used to impute missing data.
| percentage of participants | Open Label IAI |
|---|---|
| Baseline: Dry | 0.7 |
| Baseline: Not Dry | 99.3 |
| Week 52: Dry | 53.0 |
| Week 52: Not Dry | 47.0 |
| Week 100: Dry | 51.7 |
| Week 100: Not Dry | 48.3 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.
| percentage of participants | Open Label IAI |
|---|---|
| At week 52 | 25.8 |
| At week 100 | 22.5 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.
| Letters correctly read | Open Label IAI |
|---|---|
| At Week 52 | 60.1 ± 18.94 |
| Change from Baseline at Week 52 | 5.9 ± 15.54 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.
| percentage of participants | Open Label IAI |
|---|---|
| Gained ≥ 0 Letters at Week 100 | 70.9 |
| Gained ≥ 5 Letters at Week 100 | 57.6 |
| Gained ≥10 Letters at Week 100 | 40.4 |
| Gained ≥30 Letters at Week 100 | 4.6 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.
| percentage of participants | Open Label IAI |
|---|---|
| Lost >0 Letters at Week 100 | 29.1 |
| Lost ≥5 Letters at Week 100 | 23.2 |
| Lost ≥10 Letters at Week 100 | 16.6 |
| Lost ≥15 Letters at Week 100 | 13.2 |
EES included all eligible patients who were treated in the study eye, untreated in the fellow eye, had baseline specular microscopy image in both eyes, and completed week 52 evaluation in both eyes and treatment with systemic anti-VEGF therapeutics
| percent change from baseline | Open Label IAI |
|---|---|
| Week 24: Study eye | -0.3 ± 4.15 |
| Week 24: Fellow eye | 1.0 ± 4.28 |
| Week 52: Study eye | -0.2 ± 4.19 |
| Week 52: Fellow eye | -0.3 ± 4.04 |
Collected over Adverse event data were collected during the period baseline to week 100. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label IAI | — | 45/154 (29.2%) | 38/154 (24.7%) |
| Event | Open Label IAI |
|---|---|
| Cardiac failure congestiveCardiac disorders | 4/154 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/154 |
| Atrial fibrillationCardiac disorders | 3/154 |
| Coronary artery diseaseCardiac disorders | 3/154 |
| PneumoniaInfections and infestations | 3/154 |
| Acute myocardial infarctionCardiac disorders | 2/154 |
| Myocardial infarctionCardiac disorders | 2/154 |
| CellulitisInfections and infestations | 2/154 |
| SyncopeNervous system disorders | 2/154 |
| Autoimmune haemolytic anaemiaBlood and lymphatic system disorders | 1/154 |
| Event | Open Label IAI |
|---|---|
| Neovascular age-related macular degenerationEye disorders | 20/154 |
| HypertensionVascular disorders | 13/154 |
| Conjunctival haemorrhageEye disorders | 12/154 |
| Urinary tract infectionInfections and infestations | 12/154 |
| BronchitisInfections and infestations | 10/154 |
| Vitreous detachmentEye disorders | 9/154 |
| Vitreous floatersEye disorders | 9/154 |
| NasopharyngitisInfections and infestations | 9/154 |
The baseline analysis population was based on the safety analysis set (SAF) and included all patients who received at least 1 dose of study drug, regardless of the treatment for the study eye or the fellow eye.
| Age, Categorical(Participants) | Open Label IAI |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 17 |
| >=65 years | 137 |
| Sex: Female, Male(Participants) | Open Label IAI |
|---|---|
| Female | 96 |
| Male | 58 |
| Best Corrected Visual Acuity (BCVA) in the study eye (Letters Read)(letters correctly read) | Open Label IAI |
|---|---|
| Mean | 54.3 ± 13.47 |
| Central Subfield Thickness in the study eye by Optical Coherence Tomography (OCT)(micrometers (μm)) | Open Label IAI |
|---|---|
| Mean | 420.5 ± 134.90 |
| Corneal Endothelial Cell Density - Endothelial Cell Density Evaluable Set (EES)(cells/mm^2) | Open Label IAI |
|---|---|
| Study eye | 2409.8 ± 363.89 |
| Fellow eye | 2388.0 ± 383.93 |
The record gives a start of Nov 2012, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2017, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept